Welcome to our dedicated page for Angiodynamics SEC filings (Ticker: ANGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AngioDynamics, Inc. (NASDAQ: ANGO) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a medical technology company listed on the NASDAQ Global Select Market, AngioDynamics files periodic reports, proxy statements, and current reports that describe its business, governance, and financial condition.
Recent Form 8‑K filings include disclosures about quarterly and annual financial results, along with references to press releases and investor presentation slides that discuss Med Tech and Med Device performance, net sales, and the use of non‑GAAP measures such as adjusted EBITDA. Other 8‑K filings cover shareholder meeting outcomes, including voting results on director elections, auditor ratification, and advisory votes on executive compensation.
The company’s Definitive Proxy Statement (DEF 14A) provides detailed information on corporate governance, executive compensation, and its strategic organization into Med Tech and Med Device platforms. In that filing, AngioDynamics explains that Med Tech comprises high‑growth platforms such as the Auryon Atherectomy laser, Mechanical Thrombectomy products (AngioVac and AlphaVac), and NanoKnife irreversible electroporation products, while Med Device includes angiographic catheters, EVLT products, port products, and other oncology products.
On Stock Titan, investors can use AI‑powered tools to quickly interpret these filings. AI summaries highlight key points from lengthy documents, helping users understand topics such as voting results, segment structure, and the context behind reported financial metrics. Real‑time updates from EDGAR ensure that new 8‑K, 10‑K, 10‑Q, proxy, and related filings are available as soon as they are posted, while insider and governance‑related disclosures can be reviewed alongside financial and strategic information.
AngioDynamics, Inc. (NASDAQ: ANGO) filed a Form 8-K on July 15, 2025 to furnish—rather than file—materials related to its fiscal fourth-quarter and full-year results ended May 31, 2025.
- Item 2.02: The company issued a press release (Exhibit 99.1) announcing its Q4 and FY 2025 financial performance.
- Item 7.01: Investor presentation slides (Exhibit 99.2) discussing the same period were also provided.
- Both exhibits are expressly excluded from Exchange Act Section 18 liability and will not be incorporated into future Securities Act or Exchange Act filings unless specifically referenced.
- No quantitative results, guidance, or commentary appear in the 8-K text itself; investors must review the furnished exhibits for details.
The filing contains standard forward-looking-statement disclaimers and lists common risk factors that could cause actual results to differ.